journal article·2021-11

Cancer immunogenic cell death via photo-pyroptosis with light-sensitive Indoleamine 2,3-dioxygenase inhibitor conjugate

Yang Lu, Feng Xu, Yang Wang, Chao Shi, Yuzhuo Sha, Guangli He, Qichao Yao, Kun Shao, Wen Sun, Jianjun Du, Jiangli Fan, Xiaojun Peng

Biomaterials· Volume 278
Publisher page

Abstract

Immune checkpoint blockade (ICB) therapy currently considered as to be effective way to cure cancer in clinic. However, the insufficient tumor immunogenicity and the immunosuppressive tumor microenvironment always result in diminished efficacy of immunotherapy. Herein, we report the synthesis of an organic photo-immune activator NBS-1MT, the combination of photosensitizer and Indoleamine 2,3-dioxygenase (IDO) inhibitor effectively stimulates lysosomes oxidative stress the releases inflammatory cytokines. This process triggers pyroptosis for the considerable immunogenic cell death (ICD) while reversing suppressive tumor microenvironment. The photo-immune drug shows outstanding potential to activate caspase-1and then remove gasdermin-D (GSDMD), which could stimulate pyroptosis and also inhibit the tumor growth successfully in both primary and distant tumor. Furthermore, pyroptosis activated by photodynamic therapy (PDT) promotes the immune related factors release, and enhance the intratumoral infiltration of cytotoxic T lymphocytes (CTLs) with the induction of ICD of tumor cells and the cascaded synergize with IDO inhibitor, so the general antitumor immune response could be strengthened effectively. Our research confirms that the use of NBS-1MT is a promising strategy to boost the immune response and eventually to inhibit tumor growth.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Inflammasome and immune disorders · Tryptophan and brain disorders · Heme Oxygenase-1 and Carbon Monoxide

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (38)

Show source-provided references
1. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer10.1038/s41586-020-2911-7 ↗
2. Engineering prodrug nanomedicine for cancer immunotherapy10.1002/advs.202002365 ↗
3. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses10.1039/C9CS00271E ↗
4. Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors10.1021/acsnano.0c05194 ↗
5. Materialien mit Selektivität für oxidative Molekülspezies für die Diagnostik und Therapie
6. Activation of pyroptosis by membrane-anchoring AIE photosensitizer design: new prospect for photodynamic cancer cell ablation10.1002/anie.202016399 ↗
7. Targeted Magnetic Intra-Lysosomal Hyperthermia produces lysosomal reactive oxygen species and causes Caspase-1 dependent cell death10.1016/j.jconrel.2017.11.050 ↗
8. Mesoporous silica nanoparticles induced hepatotoxicityvia NLRP3 inflammasome activation and caspase-1-dependent pyroptosis10.1039/C8NR00554K ↗
9. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death10.1038/nature15514 ↗
10. A bioorthogonal system reveals antitumour immune function of pyroptosis10.1038/s41586-020-2079-1 ↗
11. Phagocyte-membrane-coated and laser-responsive nanoparticles control primary and metastatic cancer by inducing anti-tumor immunity10.1016/j.biomaterials.2020.120159 ↗
12. Targeting the tumor microenvironment with amphiphilic near-infrared cyanine nanoparticles for potentiated photothermal immunotherapy10.1016/j.biomaterials.2021.120926 ↗
13. Endoplasmic reticulum targeted AIE bioprobe as a highly efficient inducer of immunogenic cell death10.1007/s11426-020-9846-4 ↗
14. Engineering antigen as photosensitiser nanocarrier to facilitate ROS triggered immune cascade for photodynamic immunotherapy10.1016/j.biomaterials.2020.119964 ↗
15. Redox-activated porphyrin-based liposome remote-loaded with indoleamine 2,3-dioxygenase (Ido) inhibitor for synergistic photoimmunotherapy through induction of immunogenic cell death and blockage of Ido pathway10.1021/acs.nanolett.9b02306 ↗
16. Ido in the tumor microenvironment: inflammation, counter-regulation, and tolerance10.1016/j.it.2016.01.002 ↗
17. Anti-tumour immunity induces aberrant peptide presentation in melanoma10.1038/s41586-020-03054-1 ↗
18. Modularly designed peptide nanoprodrug augments antitumor immunity of PD-L1 checkpoint blockade by targeting indoleamine 2,3-dioxygenase10.1021/jacs.9b12232 ↗
19. Self-delivery photo-immune stimulators for photodynamic sensitized tumor immunotherapy10.1021/acsnano.0c06765 ↗
20. Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with Ido inhibitor for preferable cancer therapy10.1016/j.biomaterials.2019.03.027 ↗
21. Enhanced immunotherapy based on photodynamic therapy for both primary and lung metastasis tumor eradication10.1021/acsnano.7b09112 ↗
22. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy10.1002/ange.201804882 ↗
23. Radical induced quartet photosensitizers with high 1O2 production for in vivo cancer photodynamic therapy10.1007/s11426-020-9922-3 ↗
24. New Cy5 photosensitizers for cancer phototherapy: a low singlet–triplet gap provides high quantum yield of singlet oxygen10.1039/D1SC04570A ↗
25. Activity‐based NIR enzyme fluorescent probes for the diagnosis of tumors and image‐guided surgery10.1002/anie.202009796 ↗
26. Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy10.1021/acs.nanolett.8b01071 ↗
27. Activatable polymer nanoenzymes for photodynamic immunometabolic cancer therapy10.1002/adma.202007247 ↗
28. Near-Infrared light-initiated molecular superoxide radical generator: rejuvenating photodynamic therapy against hypoxic tumors10.1021/jacs.8b08658 ↗
29. Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy10.1016/j.biomaterials.2021.121018 ↗
30. Breast cancer chemo-immunotherapy through liposomal delivery of an immunogenic cell death stimulus plus interference in the Ido-1 pathway10.1021/acsnano.8b05189 ↗
31. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression10.1038/s41467-017-01651-9 ↗
32. Cell death mediated by the pyroptosis pathway with the aid of nanotechnology: prospects for cancer therapy10.1002/ange.202010281 ↗
33. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy10.1002/adma.201802228 ↗
34. Local T regulatory cells depletion by an integrated nanodrug system for efficient chem-immunotherapy of tumor10.1007/s11426-019-9507-x ↗
35. Sheddable prodrug vesicles combating adaptive immune resistance for improved photodynamic immunotherapy of cancer10.1021/acs.nanolett.9b04012 ↗
36. Charge convertible biomimetic micellar nanoparticles for enhanced melanoma-targeted therapy through tumor cells and tumor-associated macrophages dual chemotherapy with Ido immunotherapy10.1016/j.cej.2021.128659 ↗
37. Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment10.1002/adma.201803001 ↗
38. Light-triggered in situ gelation to enable robust photodynamic-immunotherapy by repeated stimulations10.1002/adma.201900927 ↗